Literature DB >> 26058806

MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A(∗)0201 alleles.

Likui Wang1, Yuefang Xu2, Cheng Luo3, Jian Sun4, Jinlu Zhang5, Ming-Wei Lee6, Aiping Bai7, Guanhua Chen8, Christopher M Frenz9, Zhengguo Li10, Wenlin Huang11.   

Abstract

MAGEA10, a cancer/testis antigens expressed in tumors but not in normal tissues with the exception of testis and placenta, represents an attractive target for cancer immunotherapy. However, suppressive cytoenvironment and requirement of specific HLA-alleles presentation frequently led to immunotherapy failure. In this study MAGEA10 was scarcely expressed in cancer patients, but enhanced by viili polysaccharides, which indicates a possibility of increasing epitopes presentation. Furthermore the correlation of gene expression with methylation, indicated by R(2) value for MAGEA10 that was 3 times higher than the value for other MAGE genes tested, provides an explanation of why MAGEA10 was highly inhibited, this is also seen by Kaplan-Meier analysis because MAGEA10 did not change the patients' lifespan. By using Molecular-Docking method, 3 MAGEA10 peptides were found binding to the groove position of HLA-A(∗)0210 as same as MAGEA4 peptide co-crystallized with HLA-A(∗)0210, which indicates that they could be promising for HLA-A(∗)0201 presentation in immunotherapy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer/tissue antigen (CTA); Epitopes; Gene expression/methylation; HLA-A(∗)0201; MAGEA10

Mesh:

Substances:

Year:  2015        PMID: 26058806     DOI: 10.1016/j.cellimm.2015.05.004

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  1 in total

1.  Analysis of risk factors for colon cancer progression.

Authors:  Zhou Yang; Yusheng Chen; Dejun Wu; Zhijun Min; Yingjun Quan
Journal:  Onco Targets Ther       Date:  2019-05-22       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.